Breaking News, Collaborations & Alliances

Bayer, Evotec Partner to Advance Precision Cardiology Therapies


Aims to identify and validate novel targets leveraging Evotec's disease modelling capabilities using human iPSCs.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bayer and Evotec have updated the focus of their strategic collaboration to develop precision treatments for cardiovascular diseases (CVDs). Financial terms were not disclosed.

   The collaboration aims to identify and validate novel targets, with the goal of building a portfolio of precision cardiology therapeutics by leveraging Evotec’s disease modelling capabilities using human induced pluripotent stem cells (iPSCs). iPSCs provide unique opportunities to identify new disease mechanis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters